Did Chelsea Handler confirm she used Ozempic?

Yes. Handler publicly confirmed her Ozempic use in January 2023, stating it was prescribed by her anti-aging doctor. She later said she discontinued the medication once she realized what it was and its association with the celebrity weight-loss trend.

Is Ozempic approved for weight loss?

No. Ozempic (semaglutide) is FDA-approved for type 2 diabetes. Wegovy, which contains the same active ingredient at a higher dose (2.4 mg), is the FDA-approved formulation for chronic weight management.

What happens when you stop taking Ozempic?

Data from the STEP 4 trial showed that participants who discontinued semaglutide regained roughly two-thirds of the weight they had lost. Current clinical guidelines recommend treating obesity as a chronic condition requiring sustained intervention.

Can any doctor prescribe Ozempic off-label?

Legally, any licensed physician can prescribe an FDA-approved medication off-label. The clinical concern is whether the prescriber has sufficient training to screen for contraindications, manage side effects, and provide appropriate monitoring, all of which are standard practice for endocrinologists and obesity medicine specialists.

What Chelsea Handler's Reported Protocol Might Look Like Clinically

By HealthRX Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

At a glance

Status: Confirmed. Handler openly discussed her Ozempic use in early 2023.
Medication: Ozempic (semaglutide 0.25 mg to 2.0 mg subcutaneous injection, weekly).
Prescriber type disclosed: Anti-aging physician, not an endocrinologist.
Indication: Off-label for weight management (Ozempic is FDA-approved for type 2 diabetes, not weight loss).
Current status: Discontinued.

The Public Record

In January 2023, Chelsea Handler told audiences she had been taking Ozempic. The comedian explained, during an appearance on the Call Her Daddy podcast, that her anti-aging doctor had prescribed the drug without fully explaining what it was. Handler said she didn't initially realize it was the same medication generating widespread celebrity buzz for weight loss. Once she understood its purpose and its association with the broader Ozempic trend, she chose to stop.

Her account was notable for its candor. Handler didn't frame the experience as a success story or an endorsement. She described it as something that happened to her, prescribed casually, taken without full context. That framing made it one of the more honest celebrity GLP-1 disclosures on record.

What Handler's story revealed was a prescribing dynamic already familiar to obesity medicine specialists: a non-specialist physician writing an off-label GLP-1 prescription for a patient who may not have met the clinical thresholds typically required for these medications.

Semaglutide: The Drug Behind the Brand

Ozempic contains semaglutide, a GLP-1 receptor agonist that mimics the incretin hormone glucagon-like peptide-1. When semaglutide binds to GLP-1 receptors in the pancreas, it stimulates glucose-dependent insulin secretion. But its effects extend well beyond blood sugar.

Semaglutide slows gastric emptying, which means food stays in the stomach longer. It also acts on hypothalamic appetite centers to reduce hunger and increase satiety signaling. These combined mechanisms produce meaningful weight loss, even in people without diabetes.

The STEP trial program demonstrated this clearly. In STEP 1, participants without diabetes who received 2.4 mg weekly semaglutide (the Wegovy dose, higher than Ozempic's maximum) lost an average of 14.9% of body weight over 68 weeks. That result led to FDA approval of Wegovy specifically for chronic weight management.

Ozempic, by contrast, remains approved only for type 2 diabetes at doses of 0.5 mg, 1.0 mg, or 2.0 mg weekly. The same molecule, different approved indication, different maximum dose.

Reconstructing the Likely Protocol

Based on Handler's public statements, what would a standard off-label Ozempic protocol from an anti-aging physician look like? The HealthRX Medical Team outlines the probable clinical pathway.

Initiation. Per the Ozempic prescribing information, treatment begins at 0.25 mg subcutaneously once weekly for four weeks. This is a tolerability phase, not a therapeutic dose. The goal is to let the GI tract adjust.

Escalation. After four weeks, the dose typically increases to 0.5 mg weekly. If the prescriber targets greater effect, the dose can go to 1.0 mg after at least four more weeks, and then to 2.0 mg. Each step requires a minimum four-week interval. Rushing escalation is one of the most common prescribing errors, as it dramatically increases nausea and vomiting rates.

Monitoring. A responsible protocol would include baseline labs (HbA1c, fasting glucose, lipid panel, renal function, thyroid panel) and periodic follow-up. The American Gastroenterological Association's 2022 clinical practice guideline on pharmacological management of obesity recommends structured follow-up for anyone on anti-obesity medications, including GLP-1 receptor agonists.

Duration. Handler reported discontinuing the drug. Clinical data from STEP 4 showed that patients who stopped semaglutide after 20 weeks regained approximately two-thirds of their lost weight within the following 48 weeks. This finding is consistent across the GLP-1 class: these medications work while you take them.

The Off-Label Prescribing Question

Handler's story matters because it names the mechanism. She didn't seek out Ozempic. An anti-aging doctor prescribed it, apparently without extensive discussion of its intended use.

Off-label prescribing is legal and sometimes medically appropriate. Physicians can prescribe FDA-approved drugs for unapproved indications if, in their clinical judgment, the evidence supports it. A 2006 analysis in Archives of Internal Medicine found that roughly 21% of all prescriptions in the United States are off-label.

The clinical issue isn't legality. It's whether the prescriber has the training and follow-up infrastructure to manage the drug's risks. GLP-1 receptor agonists carry a boxed warning about thyroid C-cell tumors based on rodent studies. They can cause pancreatitis, gallbladder events, and acute kidney injury from dehydration secondary to GI symptoms. Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not take them.

An endocrinologist or obesity medicine specialist screens for these risks as routine practice. A physician operating primarily as an anti-aging or aesthetics provider may or may not apply the same rigor.

The HealthRX Medical Team Take

Handler's experience is a useful case study, not because anything went wrong, but because she described a prescribing workflow that millions of patients encounter and rarely question.

The HealthRX Medical Team sees three clinical takeaways.

First, any patient prescribed a GLP-1 receptor agonist off-label should receive the same screening as a patient prescribed on-label. That means thyroid history, pancreatitis risk assessment, renal function, and a conversation about GI side effects. The drug doesn't behave differently because the prescriber's specialty differs.

Second, patients should know what they're taking and why. Handler's description of not realizing what Ozempic was at first is a failure of informed consent, not a failure of the medication. The AMA Code of Medical Ethics is clear: patients deserve an explanation of the nature of the treatment, its risks, its benefits, and reasonable alternatives.

Third, discontinuation planning matters. Stopping a GLP-1 agonist without a transition strategy (dietary changes, exercise programming, or switching to maintenance-dose therapy) predictably leads to weight regain. The Endocrine Society's 2024 clinical practice guideline on obesity pharmacotherapy recommends treating obesity as a chronic condition requiring long-term management, not a short course of medication.

Handler chose to stop, and that is entirely her right. The clinical point is that any prescriber initiating these medications should also plan for what happens when they end.

What Patients Should Take From This

Chelsea Handler did something uncommon among celebrities who have used GLP-1 medications: she was honest about the circumstances. She didn't frame Ozempic as a miracle. She didn't deny using it. She described a real clinical encounter, a doctor prescribing a drug without adequate explanation, and her decision to stop once she understood what it was.

For patients considering GLP-1 receptor agonists, her story carries a practical message. Ask your prescriber why they're choosing a specific medication. Ask whether the prescription is on-label or off-label. Ask about monitoring, side effect management, and what the plan looks like if you decide to stop.

The medication itself has strong clinical evidence behind it. Semaglutide produces clinically significant weight loss and cardiometabolic improvements when used appropriately. The variable isn't the drug. It's the system around it: who prescribes it, how they monitor it, and whether the patient understands what they've agreed to.

Frequently asked questions

›